Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT03772665 |
Date of registration:
|
30/11/2018 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Safety and Efficacy of Emixustat in Stargardt Disease
SeaSTAR |
Scientific title:
|
A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease |
Date of first enrolment:
|
November 7, 2018 |
Target sample size:
|
194 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03772665 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Brazil
|
Canada
|
Denmark
|
France
|
Germany
|
Italy
|
Netherlands
|
South Africa
|
Spain
|
United Kingdom
|
United States
| | | | | |
Contacts
|
Name:
|
Jeff Gregory, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
VP of Clinical Development, Acucela |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|